Novo Nordisk A/S (NYSE:NVO) Raised to Hold at Zacks Research

Novo Nordisk A/S (NYSE:NVO) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities research analysts have also commented on the company. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. BMO Capital Markets reissued a “market perform” rating and set a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday, August 6th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $64.94.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $46.52 on Tuesday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The firm has a market capitalization of $207.71 billion, a price-to-earnings ratio of 11.37, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average of $47.24 and a 200 day moving average of $44.61.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

Several large investors have recently made changes to their positions in the business. Capital Square LLC bought a new position in shares of Novo Nordisk A/S in the second quarter worth about $211,000. Somerville Kurt F bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $231,000. Trust Co. of Vermont purchased a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $1,250,000. Platform Technology Partners lifted its holdings in Novo Nordisk A/S by 39.2% in the 2nd quarter. Platform Technology Partners now owns 10,941 shares of the company’s stock worth $525,000 after purchasing an additional 3,079 shares in the last quarter. Finally, Fortis Group Advisors LLC boosted its stake in Novo Nordisk A/S by 145.5% in the 2nd quarter. Fortis Group Advisors LLC now owns 72,916 shares of the company’s stock worth $3,496,000 after purchasing an additional 43,213 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market is unlikely to be “winner-take-all,” arguing that patients will seek differentiated treatments, including pills. This supports Novo’s ability to compete beyond its current injectable products. Reuters article
• Positive Sentiment: Oral Wegovy prescriptions reportedly reached a record, while management sees a long runway for GLP-1 adoption as obesity remains widespread and treatment could eventually reduce healthcare costs. Fox Business article
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, adding a commercial opportunity in diabetes care beyond the obesity franchise. Awiqli availability article
• Neutral Sentiment: Erste Group raised its FY2026 EPS estimate to $3.27 from $3.20, although that remains below the broader consensus estimate of $3.39. Erste Group estimate article
• Negative Sentiment: Berenberg downgraded NVO from “buy” to “hold,” saying much of the anticipated Wegovy-pill upside is already reflected in the valuation and that the stock’s multiple may revert toward the European pharmaceutical average. Berenberg downgrade article
• Negative Sentiment: Management acknowledged that Eli Lilly is gaining market share. Investors remain concerned about flat Wegovy sales, pricing pressure, pipeline setbacks and Lilly’s competitive position in oral obesity treatments. BeInCrypto article
• Negative Sentiment: Novo is defending a lawsuit against Lilly over weight-loss-drug advertising. Although the company says competition must be fair, the litigation adds uncertainty and could distract from the commercial battle. CNBC article

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.